Premium
Repurposing Calsyntenin‐1 as a modulator in FSTL1‐mediated Lung Adenocarcinoma Metastasis: The Crosstalk with extracellular ALDOA
Author(s) -
Chiou Jean,
Hsiao Michael
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.02544
Subject(s) - extracellular , crosstalk , adenocarcinoma , cancer research , metastasis , microvesicles , transmembrane protein , biology , lung cancer , microbiology and biotechnology , cancer , medicine , pathology , biochemistry , microrna , receptor , gene , genetics , optics , physics
Previously, we found that FSTL1 downregulation strongly predicts a poorer prognosis in patients with lung adenocarcinoma, but not squamous‐cell carcinoma, and highly correlates with an increased metastatic potential of lung cancer cells in vitro and in vivo . To examine detail molecular mechanisms, we presented protein‐protein interaction (PPI) assays. Several proteins that belong to extracellular or exosomal members were identified by mass spectrometric analysis from the FSTL1‐interacting protein mixture. In our data, we found that CLSTN1 ranked first. CLSTN1, calsyntenin‐1, is a type‐1 neuronal transmembrane protein, which is in the postsynaptic membrane. CLSTN1 was originally identified as a transmitted protein that modulated synaptic signals with proteolytic cleavage fragment. Recent research showed that CLSTN1 overexpressed in lung adenocarcinoma tissue and released to serum. But the molecular mechanisms of CLSTN1 in lung cancer still need to be confirmed. Extracellular ALDOA was detected in lung cancer cell conditioned medium. The detail functions and mechanism of extracellular ALDOA in lung adenocarcinoma is still unclear. CLSTN1 expression in cultured medium was positive correlation with ALDOA expression in cultured medium. Collectively, we may repurpose CLSTN1 as a modulator to regulate lung adenocarcinoma metastasis and their networking, which can be used in combination with targeted therapies, chemotherapies, or radical therapies in future research.